JP2023552379A5 - - Google Patents
Info
- Publication number
- JP2023552379A5 JP2023552379A5 JP2023533861A JP2023533861A JP2023552379A5 JP 2023552379 A5 JP2023552379 A5 JP 2023552379A5 JP 2023533861 A JP2023533861 A JP 2023533861A JP 2023533861 A JP2023533861 A JP 2023533861A JP 2023552379 A5 JP2023552379 A5 JP 2023552379A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- grna
- bcl11a
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120885P | 2020-12-03 | 2020-12-03 | |
| US63/120,885 | 2020-12-03 | ||
| PCT/US2021/061672 WO2022120094A2 (en) | 2020-12-03 | 2021-12-02 | Compositions and methods for the targeting of bcl11a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552379A JP2023552379A (ja) | 2023-12-15 |
| JP2023552379A5 true JP2023552379A5 (https=) | 2024-12-06 |
Family
ID=81854906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533861A Pending JP2023552379A (ja) | 2020-12-03 | 2021-12-02 | Ｂｃｌ１１ａの標的化のための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240026386A1 (https=) |
| EP (1) | EP4255502A4 (https=) |
| JP (1) | JP2023552379A (https=) |
| KR (1) | KR20230129230A (https=) |
| CN (1) | CN116801913A (https=) |
| AU (1) | AU2021391783A1 (https=) |
| BR (1) | BR112023010717A2 (https=) |
| CA (1) | CA3200815A1 (https=) |
| CL (2) | CL2023001593A1 (https=) |
| CO (1) | CO2023007900A2 (https=) |
| GB (1) | GB2616795B (https=) |
| IL (1) | IL303359A (https=) |
| MX (1) | MX2023006565A (https=) |
| PE (1) | PE20231177A1 (https=) |
| WO (1) | WO2022120094A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230128289A (ko) | 2020-12-03 | 2023-09-04 | 스크라이브 테라퓨틱스 인크. | 조작된 클래스 2 유형 v crispr 시스템 |
| WO2022261149A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| TW202413643A (zh) | 2022-06-07 | 2024-04-01 | 美商斯奎柏治療公司 | 用於靶向pcsk9的組合物及方法 |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| US20250361525A1 (en) | 2022-06-08 | 2025-11-27 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017252023B2 (en) * | 2016-04-18 | 2024-05-02 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| MX2019003674A (es) * | 2016-09-30 | 2021-01-08 | Univ California | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. |
| CN110168084A (zh) * | 2016-12-05 | 2019-08-23 | 爱迪塔斯医药公司 | 用于内源和来源DNA的单发指导RNA(ogRNA)靶向的系统和方法 |
| US20190367924A1 (en) * | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
| CN109722414A (zh) * | 2017-10-27 | 2019-05-07 | 博雅辑因（北京）生物科技有限公司 | 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基 |
| WO2019213273A1 (en) * | 2018-05-01 | 2019-11-07 | The Children's Medical Center Corporation | Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9 |
| JP2021532815A (ja) * | 2018-08-07 | 2021-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新規Ｃａｓ１２ｂ酵素およびシステム |
-
2021
- 2021-12-02 AU AU2021391783A patent/AU2021391783A1/en active Pending
- 2021-12-02 EP EP21901487.5A patent/EP4255502A4/en active Pending
- 2021-12-02 IL IL303359A patent/IL303359A/en unknown
- 2021-12-02 WO PCT/US2021/061672 patent/WO2022120094A2/en not_active Ceased
- 2021-12-02 CN CN202180092086.3A patent/CN116801913A/zh active Pending
- 2021-12-02 GB GB2309871.8A patent/GB2616795B/en active Active
- 2021-12-02 MX MX2023006565A patent/MX2023006565A/es unknown
- 2021-12-02 CA CA3200815A patent/CA3200815A1/en active Pending
- 2021-12-02 US US18/255,172 patent/US20240026386A1/en active Pending
- 2021-12-02 PE PE2023001811A patent/PE20231177A1/es unknown
- 2021-12-02 BR BR112023010717A patent/BR112023010717A2/pt unknown
- 2021-12-02 JP JP2023533861A patent/JP2023552379A/ja active Pending
- 2021-12-02 KR KR1020237022391A patent/KR20230129230A/ko active Pending
-
2023
- 2023-06-02 CL CL2023001593A patent/CL2023001593A1/es unknown
- 2023-06-16 CO CONC2023/0007900A patent/CO2023007900A2/es unknown
-
2024
- 2024-05-27 CL CL2024001577A patent/CL2024001577A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552379A5 (https=) | ||
| US11965174B2 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| GB2616795A (en) | Compositions and methods for the targeting of BCL11A | |
| US12529051B2 (en) | Methods of treating amyotrophic lateral sclerosis (ALS) | |
| CN116949012B (zh) | 一种融合蛋白及其应用 | |
| EP3943512A1 (en) | Fusion protein for enhancing gene editing and use thereof | |
| CN111718420B (zh) | 一种用于基因治疗的融合蛋白及其应用 | |
| AU2020262281B2 (en) | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof | |
| US20190256867A1 (en) | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof | |
| US20240122989A1 (en) | Methods and compositions for production of genetically modified primary cells | |
| JP2025515030A5 (https=) | ||
| CN114072518B (zh) | 用于治疗地中海贫血或镰状细胞病的方法和组合物 | |
| WO2025056035A1 (en) | Compositions and methods for treating duchenne muscular dystrophy | |
| WO2024245152A1 (zh) | 靶向ptbp1的基因编辑系统及其应用 | |
| EP4532720A2 (en) | Crispr interference therapeutics for c9orf72 repeat expansion disease | |
| WO2026025441A1 (zh) | 一种用于显性遗传的视网膜色素变性基因编辑药物载体 | |
| EP4373846A1 (en) | A method for in vivo gene therapy to cure scd without myeloablative toxicity | |
| HK40049414A (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| WO2020187272A1 (zh) | 一种用于基因治疗的融合蛋白及其应用 | |
| HK40069063A (en) | Methods and compositions for treating thalassemia or sickle cell disease | |
| HK1240977B (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| HK1240977A1 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |